The FDA has approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with ...
Just days after gaining similar regulatory approval in the USA, AstraZeneca and Amgen’s Tezspire (tezepelumab) has been ...
Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...
The FDA approved tezepelumab-ekko (TEZSPIRE; AstraZeneca/Amgen) on Friday as an add-on maintenance treatment in patients aged ...
Patients with chronic rhinosinusitis with nasal polyps and uncontrolled asthma experienced greater improvements in lung ...
Amgen and AstraZeneca’s Tezspire (tezepelumab-ekko) gains FDA approval as an add-on maintenance therapy for patients aged 12 and older with inadequately controlled chronic rhinosinusitis with nasal ...
Investing.com -- AstraZeneca and Amgen have received European Union approval for Tezspire as an add-on therapy for adults ...
The EVEREST trial directly compared biologics in severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma, and found that dupilumab (Dupixent) was superior to ...
Drugmaker AstraZeneca said on Wednesday that its chronic rhinosinusitis with nasal polyps treatment, Tezspire, has been ...
The nasal polyps market presents opportunities with multiple pipeline drugs in various development stages, targeting novel treatment approaches. Focused efforts by key players like AstraZeneca ...
Does your nose seem to always be stuffed up? Do you have loss of taste or smell? Do you get frequent sinus infections? If so, you may have nasal polyps. Which raises the question: What exactly are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback